Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TreatHSP/SPAX Master Protocol: Adaptive Platform for Longitudinal Progression, Biomarkers and Pathophysiology in Ataxias, Hereditary Spastic Paraplegias and Spastic Ataxias (TreatHSP/SPAX)

NCT07798674 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT07798674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07798674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TreatHSP/SPAX Master Protocol: Adaptive Platform for Longitudinal Progression, Biomarkers and Pathophysiology in Ataxias, Hereditary Spastic Paraplegias and Spastic Ataxias (TreatHSP/SPAX)
Lead sponsor
Heidelberg University
Phase
Observational
Overall status
Recruiting
Start date
July 16, 2024
Completion date
December 31, 2035
Enrollment
4,000 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary spastic paraplegia, spastic ataxia